Fomivirsen Ophthalmic Side Effects

Medically reviewed by Drugs.com. Last updated on Apr 11, 2024.

Applies to fomivirsen ophthalmic: intraocular solution.

Ocular adverse events

Most adverse effects associated with fomivirsen therapy are limited to the treated eye. However, some of these events (e.g. retinal detachment) will also occur with the natural progression of CMV retinitis and may not necessarily be direct complications of drug administration.

The most frequently observed adverse effect is ocular inflammation, including iritis and vitritis. Inflammatory reactions occur in approximately 25% of patients and are more common during induction dosing. Other frequently reported ocular effects (occurring in 5% to 25% of patients) include abnormal vision, anterior chamber inflammation, blurred vision, cataract, conjunctival hemorrhage, decreased visual acuity, desaturation of color vision, eye pain, floaters, increased intraocular pressure, photophobia, retinal detachment, retinal edema, retinal hemorrhage, and retinal pigment changes. Less commonly (2% to 5%), conjunctival hyperemia, conjunctivitis, corneal edema, decreased peripheral vision, hypotony, keratic precipitates, optic neuritis, photopsia, retinal vascular disease, visual field defect, vitreous hemorrhage, and vitreous opacity have been reported.^[Ref]

Further information

Fomivirsen ophthalmic side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer